<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652795</url>
  </required_header>
  <id_info>
    <org_study_id>40074</org_study_id>
    <nct_id>NCT00652795</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Doxycycline 150 mg Tablet and Monodox 50 mg Capsule Administered as 1 x 150 mg Tablet or 3 x 50 mg Capsules in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate and extent of absorption of doxycycline tablet (Par) versus doxycycline
      capsule (Monodox)(Oclassen).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the rate and extent of absorption of doxycycline 150 mg tablet (test) versus
      Monodox 50 mg capsule (reference) administered as 1 x 50 mg tablet or 3 x 50 mg capsules
      under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Monohydrate</intervention_name>
    <description>Tablets, 150 mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Monodox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monodox</intervention_name>
    <description>Capsules 50 mg (3 x 50 mg dose), single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Doxycycline Monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-childbearing potential female, smoker or non-smokers

          -  18 years of age and older

          -  Non-childbearing potential female subjects is defined as post-menopausal state:
             absence of menses for 12 months prior to drug administration or hysterectomy with
             bilateral oophorectomy, or tubal ligation at least 6 months prior to drug
             administration

          -  Capable of consent

        Exclusion Criteria:

          -  Clinically significant illnesses within 4 weeks of the administration of study
             medication

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication

          -  Any clinically significant abnormality found during medical screening

          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the
             subject from participating in the study

          -  Abnormal laboratory tests judged clinically significant

          -  Positive testing for hepatitis B, hepatitis C or HIV at screening

          -  ECG abnormalities or vital sign abnormalities at screening

          -  BMI greater than or equal to 30.0 kg/m2

          -  History of significant alcohol abuse within six months of the screening visit or any
             indication of the regular use of more than fourteen units of alcohol per week

          -  History of drug abuse or use of illegal drugs: soft drugs (marijuana) within 3 months
             prior to the screening visit or hard drugs (cocaine, PCP, crack) within 1 year prior
             to the screening visit or positive urine drug screen at screening

          -  History of allergic reactions to heparin, doxycycline, or other related drugs

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days
             prior to administration of the study medication

          -  Use of an investigational drug or participation in an investigational study, within 30
             days prior to administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism, or excretion of the drug

          -  Any clinically significant history or presence of clinically significant neurological,
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or
             metabolic disease

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products within 7 days prior to administration of study
             medication, except for topical products without systemic absorption

          -  Difficulty to swallow study medication

          -  Smoking more than 25 cigarettes per day Any food allergy, intolerance, restriction or
             special diet that, in the opinion of the Medical Sub-Investigator, could
             contraindicate the subject's participation in the study A depot injection or an
             implant of any drug within 3 months prior to administration of study medication

          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or
             loss of whole blood (excluding the volume of blood that will be drawn during the
             screening procedures of this study)prior to the administration of the study medication
             (50 mL to 300 mL of whole blood within 30 days, 301 mL to 500 mL of whole blood within
             45 days, or more than 500 mL of whole blood within 56 days prior to drug
             administration)

          -  History or presence of clinically significant gastro-oesophageal reflux, stomach
             ulcers, or indigestions

          -  History or presence of clinically significant severe renal or hepatic dysfunction

          -  History or presence of clinically significant myasthenia gravis

          -  Breast-feeding subject

          -  Positive urine pregnancy screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 1, 2008</last_update_submitted>
  <last_update_submitted_qc>April 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alfred Elvin/Director of Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>doxycycline monohydrate</keyword>
  <keyword>fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

